Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB).

The results are based on the final analyses of the RewinD-LB trial, conducted after the August 2025 database lock for the full 48-week trial (16 weeks placebo-controlled (Initial Phase), followed by a 32-week neflamapimod-only extension (Extension Phase)).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.